GlassScriptPhysician profile
Alexander Toirac
NPI 1205367893
$9,869.39
in general payments reported to CMS, 2019-2025
15 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,237 · 2022: $321 · 2023: $3,175 · 2024: $1,864 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,601 · Travel and Lodging: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,601.11 |
| Travel and Lodging | $2,710.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,198.86 | 2023-2025 | Watchman Flx, Watchman Access System |
| Abbott Laboratories | $3,053.54 | 2022-2025 | Ensite Precision, Triclip, Mitraclip |
| Biotronik INC. | $2,223.40 | 2021-2022 | |
| Medtronic, INC. | $307.18 | 2021-2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $214.46 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $153.38 | 2025 | Mitris Resilia Mitral Valve |
| Amgen INC. | $141.65 | 2022-2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $107.18 | 2024 | Arcalyst |
| Novo Nordisk INC | $102.60 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $100.51 | 2023-2025 | Wainua, Farxiga |
| Abiomed | $95.44 | 2024-2025 | Impella |
| Pfizer INC. | $63.42 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $58.17 | 2024 | |
| Lilly USA, LLC | $25.22 | 2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Toirac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.